Targeting tyrosine kinases in ovarian cancer: small molecule inhibitor and monoclonal antibody, where are we now?

HIGHLIGHTS

  • who: Aimee Rendell and collaborators from the Curtin Medical School, Faculty of Health Sciences, Curtin University, Perth, WA, Australia have published the paper: Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?, in the Journal: Biomedicines 2022, 2113 of /2022/
  • what: The study showed that the protein expressions of VEGF-A, VEGF-D, and VEGFR1 were higher in the metastases than the primary lesions .
  • future: Whilst further study will be required to dissect the exact mechanism of each receptor in isolation the ROR family represents a . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?